H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Tuesday, setting a price target of $40, which is approximately 25.04% above the present share price of $31.99.
Selvaraju expects Genmab A/S to post earnings per share (EPS) of $0.41 for the second quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Genmab, with an average price target of $36.
The analysts price targets range from a high of $40 to a low of $30.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $892 million and a net profit of $71 million. The company's market cap is $21.25 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 27.5% and a 58.58% success rate.
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.